Diagnostics (Basel, Switzerland) · 2024
An Overview of Gaucher Disease.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Méndez-Cobián Daniela Anahí, Guzmán-Silahua Sandra, García-Hernández Diana, Conde-Sánchez Julian, Castañeda-Borrayo Yaocihuatl, Duey Kylee Louise, Zavala-Cerna Maria G, Rubio-Jurado Benjamín, Nava-Zavala Arnulfo Hernán
Аннотация
BACKGROUND: Gaucher disease (GD) is a rare autosomal recessive disorder caused by mutations in the GBA1 gene that lead to a deficiency in the glucocerebrosidase gene. This deficiency results in the accumulation of glucocerebrosides in macrophages, primarily affecting the liver, spleen, and bone marrow. Focusing on the Mexican population, this study aims to review GD's epidemiology, clinical manifestations, and treatment options to enhance early diagnosis and optimize treatment outcomes.
METHODS: This study is a comprehensive literature review analyzing epidemiological data, clinical presentations, and current therapeutic approaches for Gaucher disease, including enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).
CONCLUSIONS: Early diagnosis and individualized treatment, primarily through enzyme replacement therapy, significantly improve the prognosis of patients with Gaucher disease, particularly type 1. Continued research is required to enhance therapeutic approaches for the neuropathic types and better understand the disease's epidemiology in Mexico. These efforts will contribute to improved clinical outcomes and quality of life for patients.
METHODS: This study is a comprehensive literature review analyzing epidemiological data, clinical presentations, and current therapeutic approaches for Gaucher disease, including enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).
CONCLUSIONS: Early diagnosis and individualized treatment, primarily through enzyme replacement therapy, significantly improve the prognosis of patients with Gaucher disease, particularly type 1. Continued research is required to enhance therapeutic approaches for the neuropathic types and better understand the disease's epidemiology in Mexico. These efforts will contribute to improved clinical outcomes and quality of life for patients.